Pfizer (PFE.US) completed clinical trials for a drug called Paxlovid, which aims to reduce the risk of severe coronavirus infection. The researchers announced that their tests suggested that taking Paxlovid orally reduces the risk of severe disease or even death by almost 89%.
Paxlovid refers to the overall treatment, which consists of taking ritonavir, an HIV antiviral drug, and new molecules created by scientists at Pfizer that were originally intended to counteract SARS infection nearly two decades ago. The medicine is in the form of three tablets taken twice a day. Company assured that test results will be immediately sent to the Food and Drug Administration (FDA), which is to approve the use of the drug in life-threatening situations.
Start investing today or test a free demo
Create account Try a demo Download mobile app Download mobile app"These data suggest that our oral antiviral candidate, if approved by regulatory authorities, has the potential to save patients' lives, reduce the severity of COVID-19 infections, and eliminate up to nine out of ten hospitalizations,'' Pfizer CEO Albert Bourla said in a statement. The reported effectiveness of the drug is therefore greater compared to the drug molnupiravir from Merck & Co Inc., which reduces the risk by half (preliminary information).
The company plans to produce 180,000 packages of the drug by the end of the year and at least 50 million by the end of 2022. Experts also remind that vaccines are still the most effective way to protect against COVID.
Pfizer's stock (PFE.US) launched today's session with a massive bullish price gap, while shares of its main competitors Merck MRK.US) and Moderna (MRNA.US) plunged. Source:xStation5
The content of this report has been created by XTB S.A., with its registered office in Warsaw, at Prosta 67, 00-838 Warsaw, Poland, (KRS number 0000217580) and supervised by Polish Supervision Authority ( No. DDM-M-4021-57-1/2005). This material is a marketing communication within the meaning of Art. 24 (3) of Directive 2014/65/EU of the European Parliament and of the Council of 15 May 2014 on markets in financial instruments and amending Directive 2002/92/EC and Directive 2011/61/EU (MiFID II). Marketing communication is not an investment recommendation or information recommending or suggesting an investment strategy within the meaning of Regulation (EU) No 596/2014 of the European Parliament and of the Council of 16 April 2014 on market abuse (market abuse regulation) and repealing Directive 2003/6/EC of the European Parliament and of the Council and Commission Directives 2003/124/EC, 2003/125/EC and 2004/72/EC and Commission Delegated Regulation (EU) 2016/958 of 9 March 2016 supplementing Regulation (EU) No 596/2014 of the European Parliament and of the Council with regard to regulatory technical standards for the technical arrangements for objective presentation of investment recommendations or other information recommending or suggesting an investment strategy and for disclosure of particular interests or indications of conflicts of interest or any other advice, including in the area of investment advisory, within the meaning of the Trading in Financial Instruments Act of 29 July 2005 (i.e. Journal of Laws 2019, item 875, as amended). The marketing communication is prepared with the highest diligence, objectivity, presents the facts known to the author on the date of preparation and is devoid of any evaluation elements. The marketing communication is prepared without considering the client’s needs, his individual financial situation and does not present any investment strategy in any way. The marketing communication does not constitute an offer of sale, offering, subscription, invitation to purchase, advertisement or promotion of any financial instruments. XTB S.A. is not liable for any client’s actions or omissions, in particular for the acquisition or disposal of financial instruments, undertaken on the basis of the information contained in this marketing communication. In the event that the marketing communication contains any information about any results regarding the financial instruments indicated therein, these do not constitute any guarantee or forecast regarding the future results.
